Loading
CTNNB1 (Catenin beta-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Colorectal cancer, Ovarian cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Key downstream component of the canonical Wnt signalling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Also acts as a coactivator for other transcription factors, such as NR5A2. Promotes epithelial to mesenchymal transition/mesenchymal to epithelial transition (EMT/MET) via driving transcription of CTNNB1/TCF-target genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Location: Cytoplasm; Nucleus; Cytoplasm, cytoskeleton; Cell junction, adherens junction (UniProt). Locus 3p22.1 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 5-7% | Activating mutation or large in-frame deletion | cBioPortal: 503 of 7,237, 7.0%, in crc_msk_2026; 84 of 1,134, 7.4%, in crc_msk_2017; 106 of 1,516, 7.0%, in crc_eo_2020; 33 of 534, 6.2%, in coadread_tcga_pan_can_atlas_2018; 36 of 619, 5.8%, in coadread_dfci_2016. Structural variants disrupt CTNNB1 in 29 of 7,237 crc_msk_2026 samples. Large in-frame CTNNB1 deletions, missed by standard variant calling, were part of what took WNT alteration to 96% of tumours (Yaeger 2018). | cBioPortal (TCGA) |
| Gallbladder cancer | 6% | Mutation (Wnt activation) | Mutation in 15 of 244 samples, 6.1%, in cBioPortal gbc_mskcc_2022 and 6 of 103, 5.8%, in gbc_msk_2018; a significantly mutated gene not previously linked to gallbladder cancer, with recurrent Wnt pathway alterations (Pandey 2020); a critical event in co-existing adenoma, high-grade BilIN and carcinoma lesions (Lin 2021). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CTNNB1" OR ABSTRACT:"CTNNB1" OR TITLE:"catenin beta 1" OR ABSTRACT:"catenin beta 1" OR TITLE:"Catenin beta-1" OR ABSTRACT:"Catenin beta-1" OR TITLE:"beta-catenin" OR ABSTRACT:"beta-catenin" OR TITLE:"armadillo" OR ABSTRACT:"armadillo" OR TITLE:"CTNNB" OR ABSTRACT:"CTNNB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNNB1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ctnnb1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ctnnb1.json. Licence CC BY-NC 4.0.